Frances Lasowski
CEO
20/20 OptimEyes Technologies
Hamilton, Canada
Frances Lasowski is the CEO of 20/20 OptimEyes Technologies, developing a mucoadhesive nanoparticle platform that enables sustained, localized drug delivery across mucosal tissues. She brings deep expertise in polymer engineering and drug delivery.
My organisation
About me
I’m a polymer scientist and CEO of 20/20 OptimEyes Technologies, where we’re advancing a mucoadhesive nanoparticle platform designed to improve how drugs are delivered across mucosal surfaces. My background is in chemical and biomedical engineering, with a focus on translating materials science into practical therapeutic solutions.
My work sits at the intersection of formulation science, drug delivery, and product development. I’m particularly interested in approaches that can meaningfully improve patient adherence and outcomes without requiring entirely new drugs.
I’m looking to connect with partners who see the value of enabling technologies and are interested in applying them across multiple indications — from ophthalmology to broader mucosal delivery opportunities.